Cervical cancer vaccine to launch in a few months, priced between ₹200-400: Adar Poonawalla

Cervical cancer vaccine to launch in a few months, priced between ₹200-400: Adar Poonawalla

Adar Poonawalla stated that the Cervical cancer vaccine would first be accessible through the government channel and beginning next year, private partners would be included as well.

SII’s Adar Poonawalla said on 1 September that India’s first indigenously developed Quadrivalent Human Papillomavirus (qHPV) vaccine for the cervical cancer will be launched in a couple of months. The qHPV vaccine is a major breakthrough in the fight against cervical cancer and will be a crucial tool in protecting women’s health.

He further said that the cervical cancer vaccine will be available to the people in an affordable price range of ₹200-400.
Adar Poonawalla announced on Thursday, along with Union Minister of Science and Technology Jitendra Singh, that the cervical cancer vaccine will be very cost effective and available within the range of ₹200-400. Poonawalla stated that although the final price has not been decided, scientific completion of the vaccine implies that R&D activities are finished and the next step to make them available to the public will soon follow.

Singh spoke at the event, raising awareness about the importance of preventive healthcare in light of Covid. He said that the development of vaccines, like the one against cervical cancer, is a direct result of this heightened awareness.

“The schemes like Ayushman Bharat have made us think about preventive healthcare and we can now afford it,” said the Department of Biotechnology’s lead in the matter. “We are in collaborative mode.”

“I believe that scientific efforts are often unrecognized and this event is to celebrate that,” he said.

Poonawalla said that the vaccine would be made available first through the government channel, with private partners getting involved next year.

Poonawalla stated that 200 million doses have been planned and that the vaccine will first be given to citizens of India before it is exported to other countries.

Over 2000 volunteers participated from across the country in this vaccine research project, said Rajesh Gokhale, Department of Biotechnology Secretary. He went on to say that partnerships between private and public entities are becoming increasingly important in such research, and that this “co-creation” is what will make all the difference in the world.

Dr. N. Kalasselvi, Director General of CSIR, expressed her sentiments regarding the qHPV vaccine CERVAVAC, calling it the first stepping stone in the field of research that will continue to evolve. “This government has taken a great deal of care to come up with this type of innovation, making us ‘atmanirbhar’,” she said. officials stated that the qHPV vaccine CERVAVAC has demonstrated a robust antibody response that is nearly 1,000 times higher than the baseline against all targeted HPV types and in all dose and age groups.

Cervical cancer is the second most common cancer among women in India between the ages of 15 and 44. In July, the Drugs Controller General of India (DCGI) granted market authorization to the SII to manufacture a vaccine against cervical cancer.